Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07577856 Guselkumab/Golimumab Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577856 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261803 Savolitinib c-Met positive Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261803 clinical trial report covering Savolitinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Ramucirumab Biologics Sequence Review Report 2026: VEGFR-2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ramucirumab, an antibody targeting VEGFR-2.
Latest Hotspot
8 min read
NCT07578363 Apraclonidine Hydrochloride Eye Redness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578363 clinical trial report covering Apraclonidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07578649 SSGJ-707 MSS/pMMR/MSI-L Endometrial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578649 clinical trial report covering SSGJ-707, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Faricimab Biologics Sequence Review Report 2026: VEGF-A/ANG-2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Faricimab, a bispecific antibody targeting VEGF-A/ANG-2.
Latest Hotspot
8 min read
NCT07577804 HSK-31858 Bronchiectasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577804 clinical trial report covering HSK-31858, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07578116 Trastuzumab Oligometastatic Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578116 clinical trial report covering Trastuzumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Brolucizumab Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brolucizumab, an antibody fragment targeting VEGF-A.
Latest Hotspot
8 min read
NCT07579234 Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharma Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07579234 clinical trial report covering Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharma, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07582432 Immune Globulin (Human)(Grifols) Secondary Antibody Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07582432 clinical trial report covering Immune Globulin (Human)(Grifols), Phase 3, endpoints, sponsor, geography, readout timing and development white spac
6 min read
Ranibizumab Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ranibizumab, an antibody fragment targeting VEGF-A.